Antibody-drug conjugate · Cytotoxic, directed at leucine-rich repeat-containing protein 15 (LRRC15) · developed by Zai Lab Co.
ZL-6201 is an antibody-drug conjugate that pairs a humanized antibody binding LRRC15, a tumor-associated antigen expressed on tumor cells and cancer-associated fibroblasts, with the camptothecin topoisomerase-1 inhibitor C24 through a protease-cleavable linker. After internalization, the released payload inhibits topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in solid tumors and sarcomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07374848 | Phase 1 | Solid Tumors | Recruiting | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
SarcomasSolid Tumors
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →